Lazertinib, Yuhan’s clinical candidate which is a third-generation EGFR tyrosine kinase inhibitor, was being developed for the treatment of patients with non-small cell lung cancer (“NSCLC”).

At the time of engaging PharmaVentures, Yuhan had been in dialogue with a number of potential licensees. In order to strengthen the Lazertinib story, Yuhan requested PharmaVentures to conduct a comprehensive valuation of the asset, which included the following:

• Market assessment, including epidemiology, clinical trials, competitor activity, market precedence on uptake levels and peak shares
• Risk-adjusted eNPV/DCF model
• Comparable deal and company benchmarking
• Deal structuring

On 5th November 2018, Yuhan announced that it had entered into a deal with Janssen Biotech, with an upfront payment to Yuhan of US$50 million and potentially up to $1.205 billion in development and commercial milestones.